|
Dr. Shorr served as Vice President Science and Technology and as Vice President for Research and Development at Enzon Inc. (NASDAQ:ENZN). Dr. Shorr was responsible for management of the co-development, with Schering Plough, of a longer acting less frequent dosing form of alfa interferon. The product, PEG INTRON A, is now approved in the US and Europe. While at Enzon, Dr. Shorr was also responsible with senior management for the acquisition of GENEX and the platform technology patent estate for single chain antibodies as well as in-licensing and out-licensing business development activities. Dr. Shorr was also responsible for the ground-up establishment of both preclinical and clinical development infrastructure and facilities, including CGMP fermentation and protein production and PEGylation manufacturing capability, synthetic chemistry, analytical chemistry, pharmacology and toxicology functions to support clinical trials. In addition to PEG INTRON A, Dr. Shorr established an anticancer program serving as the basis for PEG Hemoglobin radiation sensitization and PEG-paclitaxel and PEG camptothecin for solid tumor treatment clinical trials. Programs evaluating PEG Hemoglobin as a blood substitute, PEG glucocerebrosidase for the treatment of Gaucher disease and PEG adenosine deaminase for the treatment of HIV/AIDS was also established. | 